Skye Bioscience, Inc. (SKYE)
0.9901
-0.05
(-4.80%)
USD |
NASDAQ |
Nov 06, 10:25
Skye Bioscience EPS Diluted (Quarterly) : -2.174 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.174 |
| March 31, 2026 | -2.522 |
| December 31, 2025 | -2.912 |
| September 30, 2025 | -2.572 |
| June 30, 2025 | -3.555 |
| March 31, 2025 | -2.240 |
| December 31, 2024 | -1.951 |
| September 30, 2024 | -0.8034 |
| June 30, 2024 | -1.635 |
| March 31, 2024 | -1.434 |
| December 31, 2023 | -2.863 |
| September 30, 2023 | -25.32 |
| June 30, 2023 | -6.40 |
| March 31, 2023 | -10.98 |
| December 31, 2022 | -31.50 |
| September 30, 2022 | -12.62 |
| June 30, 2022 | -13.78 |
| March 31, 2022 | -12.28 |
| December 31, 2021 | -10.56 |
| September 30, 2021 | -8.82 |
| June 30, 2021 | -10.70 |
| March 31, 2021 | -12.82 |
| December 31, 2020 | -10.44 |
| September 30, 2020 | -13.38 |
| June 30, 2020 | -15.52 |
| Date | Value |
|---|---|
| March 31, 2020 | -25.70 |
| December 31, 2019 | -27.80 |
| September 30, 2019 | -0.0371 |
| June 30, 2019 | 168.22 |
| March 31, 2019 | -222.62 |
| December 31, 2018 | -92.94 |
| September 30, 2018 | -31.90 |
| June 30, 2018 | -40.00 |
| March 31, 2018 | -180.00 |
| December 31, 2017 | -57.18 |
| September 30, 2017 | -40.00 |
| June 30, 2017 | -40.00 |
| March 31, 2017 | -180.00 |
| December 31, 2016 | -140.00 |
| September 30, 2016 | -100.00 |
| June 30, 2016 | 60.00 |
| March 31, 2016 | -160.00 |
| December 31, 2015 | -69.46 |
| September 30, 2015 | -140.00 |
| June 30, 2015 | -260.00 |
| March 31, 2015 | -120.00 |
| December 31, 2014 | -212.82 |
| September 30, 2014 | -67.80 |
| April 30, 2014 | -3.161 |
| January 31, 2014 | 0.8475 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -10.79M |
| Total Expenses (Quarterly) | 10.79M |
| Enterprise Value | -5.317M |
| Earnings Yield | -1.03K% |
| Normalized Earnings Yield | -981.92 |